In five trials (Thurlimann et al, 1996; Nabholtz et al, 2000; Mouridsen et al, 2001; Milla-Santos et al, 2003; Paridaens et al, 2004), more than 65% of the patients had hormone receptor-positive tumours compared with only 43% in the three remainder studies (Perez Carrion et al, 1994; Falkson and Falkson, 1996; Bonneterre et al, 2000). Here, NR4A1 is linked to neoplasm.